Narita, Shintaro http://orcid.org/0000-0003-2988-1860
Kimura, Takahiro
Hatakeyama, Shingo
Hata, Kenichi
Yanagisawa, Takafumi
Maita, Shinya
Chiba, Shuji
Sato, Hiromi
Kashima, Soki
Koizumi, Atsushi
Yamamoto, Ryohei
Takayama, Koichiro
Okane, Katsumi
Ishida, Toshiya
Horikawa, Yohei
Kumazawa, Teruaki
Shimoda, Jiro
Suzuki, Takehiro
Ohyama, Chikara
Egawa, Shin
Habuchi, Tomonori
Article History
Received: 1 April 2022
Accepted: 4 June 2022
First Online: 24 June 2022
Declarations
:
: Shintaro Narita received honoraria from Janssen Pharmaceutical K.K. Takahiro Kimura is a paid consultant/advisor of Astellas Pharma Inc., Bayer AG, Janssen Pharmaceutical K.K and Sanofi S.A. Shin Egawa is a paid consultant/advisor of Takeda, Astellas, AstraZeneca, Sanofi, Janssen, and Pfizer. Shingo Hatakeyama received honoraria from Janssen Pharmaceutical K.K. and Pfizer Inc. and Nipro Corporation. Chikara Ohyama received honoraria from Astellas Pharma Inc., NIPPON SHINYAKU Company Ltd., AstraZeneca K.K., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Company Ltd., Novartis Pharma K.K., ONO Pharmaceutical Company Ltd., Chugai Pharmaceutical Company Ltd., Sanofi S.A., Bayer AG., Pfizer Inc., Bristol Myers Squibb, Otsuka Pharmaceutical Company Ltd., KISSEI Pharmaceutical Company Ltd., Kyowa Kirin Company Ltd., Daiichi Sankyo Company Ltd., KANEKA Corporation, and Nipro Corporation. Tomonori Habuchi also received honoraria from Janssen Pharmaceutical K.K., Takeda Pharmaceutical Company Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Ltd., AstraZeneca K.K., Sanofi S.A., and Bayer AG. The other authors have no disclosures.
: All patients gave opt-out consent for inclusion after being informed of the study and provided information on the institution’s website.
: The study involves human participants.
: The retrospective multicenter study was approved by each institutional review board and representative facility (A2018-03).